Aron Knickerbocker

Aron Knickerbocker is president and CEO of Aulos Bioscience and is a member of the board of directors. Prior to Aulos, he was chairman and CEO and a co-founder of RayzeBio, a targeted radiopharmaceutical company. Previously, Aron held a variety of executive positions during ten years at Five Prime Therapeutics, most recently president and CEO. Aron was responsible for licensing bemarituzumab into Five Prime, prioritizing it in the portfolio, and driving its advancement into the randomized trial that recently demonstrated a significant overall survival benefit when added to chemotherapy as first-line treatment for advanced gastric cancer. He significantly expanded the clinical pipeline, established multiple transformational strategic alliances, and was instrumental in taking Five Prime public. Before Five Prime, Aron worked at Genentech for over eight years as head of oncology business development. He orchestrated many key collaborations, including those that led to the marketed products VENCLEXTAS, COTELLIC", and ERIVEDGEU. Prior to Genentech, Aron worked in commercial development at A1-ZA (acquired by Johnson & Johnson), corporate development at Amgen, and research at Bristol-Myers Squibb. Aron serves on the boards of KAHR Medical Ltd. and Phenomic A1.

Aron received an A.B. with honors in biology from Washington University in St. Louis, and an M.B.A. with distinction from the University of Michigan.